TD Cowen analyst Ritu Baral raised the firm’s price target on Palvella Therapeutics (PVLA) to $190 from $133 and keeps a Buy rating on the shares. The firm said they have high conviction QTORIN rapa will receive BTD in cVM, which could allow FDA alignment on a single-arm Ph3 design, expediting data and approval.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics announces publication of review on Qtorin
- 3 Best Stocks to Buy Today, 2/2/2026, According to Top Analysts
- Palvella Highlights QTORIN Rapamycin Progress in New Presentation
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts
- Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics